Based on early negotiations with payers, Esperion Therapeutics Inc. is counting on preferred formulary status and reasonable out-of-pocket copays for its oral cholesterol drug bempedoic acid, which just passed its final Phase III study, putting to rest concerns about safety and paving the way for filings in 2019.
Bempedoic acid is a first-in-class once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers LDL-cholesterol (LDL-C) through...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
